TG Therapeutics, Inc.
TGTX
$42.54
-$0.60-1.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 6.41% | 19.09% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.41% | 19.09% | |||
| Cost of Revenue | -12.14% | 35.77% | |||
| Gross Profit | 10.99% | 15.58% | |||
| SG&A Expenses | 40.60% | -0.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.74% | 7.36% | |||
| Operating Income | -31.09% | 71.95% | |||
| Income Before Tax | -54.84% | 74.04% | |||
| Income Tax Expenses | -97.34% | 106.04% | |||
| Earnings from Continuing Operations | -14.15% | -94.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -14.15% | -94.11% | |||
| EBIT | -31.09% | 71.95% | |||
| EBITDA | -31.06% | 71.92% | |||
| EPS Basic | -15.02% | -94.01% | |||
| Normalized Basic EPS | -35.21% | 76.93% | |||
| EPS Diluted | -14.65% | -94.21% | |||
| Normalized Diluted EPS | -34.79% | 75.75% | |||
| Average Basic Shares Outstanding | 1.03% | -1.69% | |||
| Average Diluted Shares Outstanding | 0.44% | -1.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||